Genetic features of NPM1− MN, NPM1+ MN, and NPM1+ AML cohorts
| . | NPM1− MN (n = 95) . | NPM1+ MN (n = 45) . | NPM1+ AML (n = 119) . |
|---|---|---|---|
| Comutations, by pathway, n (%) | |||
| DNMT3A | 14 (15)* | 15 (33) | 57 (48) |
| IDH1 | 22 (2) | 4 (9)* | 25 (21)* |
| IDH2 | 5 (5) | 2 (4)* | 16 (13)* |
| TET2 | 29 (31) | 7 (16) | 32 (27) |
| ASXL1 | 30 (32)* | 4 (9) | 3 (3) |
| RUNX1 | 20 (21)* | 0 (0) | 1 (0.8) |
| KRAS | 3 (3) | 1 (2)† | 4 (3)† |
| NRAS | 8 (8) | 4 (9)† | 27 (23)† |
| FLT3 (non-ITD) | 1 (1) | 3 (7) | 29 (24)‡ |
| FLT3-ITD | 1 (1) | 1 (2) | 36 (30)‡ |
| PTPN11 | 2 (2)* | 6 (13) | 25 (21) |
| SRSF2 | 20 (21) | 3 (8) | 9 (8) |
| SF3B1 | 9 (9) | 4 (9) | 1 (0.8) |
| TP53 | 15 (16)* | 1 (2) | 0 (0) |
| Mutation count, median (range) | 2 (0-8) | 2 (1-7) | 4 (1-8)§ |
| Abnormal karyotype, n (%) | 57 (61)* | 5 (12) | 18 (16) |
| . | NPM1− MN (n = 95) . | NPM1+ MN (n = 45) . | NPM1+ AML (n = 119) . |
|---|---|---|---|
| Comutations, by pathway, n (%) | |||
| DNMT3A | 14 (15)* | 15 (33) | 57 (48) |
| IDH1 | 22 (2) | 4 (9)* | 25 (21)* |
| IDH2 | 5 (5) | 2 (4)* | 16 (13)* |
| TET2 | 29 (31) | 7 (16) | 32 (27) |
| ASXL1 | 30 (32)* | 4 (9) | 3 (3) |
| RUNX1 | 20 (21)* | 0 (0) | 1 (0.8) |
| KRAS | 3 (3) | 1 (2)† | 4 (3)† |
| NRAS | 8 (8) | 4 (9)† | 27 (23)† |
| FLT3 (non-ITD) | 1 (1) | 3 (7) | 29 (24)‡ |
| FLT3-ITD | 1 (1) | 1 (2) | 36 (30)‡ |
| PTPN11 | 2 (2)* | 6 (13) | 25 (21) |
| SRSF2 | 20 (21) | 3 (8) | 9 (8) |
| SF3B1 | 9 (9) | 4 (9) | 1 (0.8) |
| TP53 | 15 (16)* | 1 (2) | 0 (0) |
| Mutation count, median (range) | 2 (0-8) | 2 (1-7) | 4 (1-8)§ |
| Abnormal karyotype, n (%) | 57 (61)* | 5 (12) | 18 (16) |
IDH1 and IDH2 are grouped for the analysis comparing NPM1+ MN with NPM1+ AML (Fisher's exact test).
KRAS and NRAS are grouped for the analysis comparing NPM1+ MN with NPM1+ AML (Fisher's exact test).
Significantly different compared with NPM1+ MN (Fisher's exact test).
P < .05 for difference compared with NPM1+ MN (Mann-Whitney U test).